(Philadelphia, PA) - Researchers at the University
of Pennsylvania School of Medicine discovered that a protein
called Elk-1 interacts with mitochondria, the energy storehouse
of a cell, suggesting that this protein - typically active in the
nucleus - could play a role in cell death, and mitochondria-related
diseases such as neurodegeneration and schizophrenia.
The neuron is a particular type of cell in the brain that is responsible
for, among other tasks, learning and memory, cognitive function,
and other higher order physiologies. The neuronal cell exhibits
a complex structure where fine hairlike structures called dendrites
receive signals from other neurons. These signals are transferred
to the soma, or body, of the cell and result in neuronal responsiveness
to stimulation.
The
researchers found that mRNA (messenger RNA) and protein encoding
Elk-1, a transcription factor, were localized in the dendrites of
intact rodent neurons. “Transcription factors normally only
function in the nucleus and to find a transcription factor in the
dendrite is pretty unique,” says senior author James
Eberwine, PhD, Professor of Pharmacology. “These
factors are proteins that bind to DNA and play a role in the regulation
of gene expression by promoting transcription. Our lab and others
showed that Elk-1 is present in the dendrites of nerve cells.”
Transcription is the process of translating the DNA code into protein.
Along with Eberwine, co-authors Lindy Barrett, PhD,
a student from the Eberwine lab who was recently awarded her doctorate
in philosophy; Philip Haydon, PhD, Professor of
Neuroscience; Jai Yoon Sul, PhD, a postdoctoral
fellow in the Haydon lab; and colleagues published their findings
in the June issue of Nature Methods and a March issue of
the Proceedings of the National Academy of Sciences.
In the series of experiments (described in the PNAS study) to discern
the nature of Elk-1’s role in the dendrite, the investigators
first characterized some of the proteins with which Elk-1 interacts,
and found that Elk-1 associates with mitochondria proteins. Mitochondria
are distributed throughout cells, including in the dendrites, and
are important in maintaining the energy stores and regulating viability
and death of the cell.
The
researchers then overexpressed Elk-1 in rat neurons to see if there
was an effect on cell viability. “We thought that through
interaction with Elk-1, the mitochondria would be able to regulate
cell death,” says Eberwine. “By overexpressing Elk-1,
we found that we did decrease cell viability, achieving more cell
death. Conversely, when we knock-down Elk-1 expression, the survivability
of neurons increased, which indicates that Elk-1 plays a role in
neuron viability.”
Cell-death is a component of a number of psychiatric and neurological
diseases such as schizophrenia and those that involve neurodegeneration.
For many of these diseases dysfunction of the dendrite is also associated
with the disease process. “Therefore, anything that impacts
dendrite function might be associated with illness,” surmises
Eberwine. “The fact that Elk-1 RNA and protein are present
in dendrites, and the fact that Elk-1 can modulate cell viability,
potentially through the mitochondria, suggests that Elk-1 could
play a role in these diseases perhaps through modulation of mitochondrial
activity.”
To more precisely understand the role of Elk-1 RNA in the dendrite,
the researchers developed a method called phototransfection, which
was described in their June Nature Methods paper, to focally introduce
Elk-1 RNA into the dendrite. In this technique, a laser light beam
is used to create small transient pores in the membrane of intact
rat nerve cells, into which a known amount of RNA molecules are
introduced by diffusion.
The introduction and translation of Elk-1 mRNA in dendrites by phototransfection
also elicited cell death whereas introduction and translation of
Elk-1 mRNA in the cell soma did not produce cell death. The Elk-1
proteins translated in the dendrites were transported to the nucleus
and cell death depended on subsequent transcription. These results
compliment and expand upon the PNAS study in which Elk-1’s
involvement in cell death and association with mitochondria were
elucidated.
“This is the first formal proof that RNA can be translated
and made into protein in an intact neuronal dendrite,” explains
Eberwine. “We have seen this with isolated dendrites before,
but not in an intact cell.”
In the mouse model, Elk-1 mRNA is being made into protein on ribosomes
located at the periphery of the nerve cell in the dendrite. Protein
is also being made in the cell body, but there may be a difference
in the Elk-1 protein made in the cell body. “We speculate
that the dendrite’s environment comes into play, with kinases
and phosphatases that modify the Elk-1 proteins made in the dendrite,”
explains Eberwine. “We suggest that there’s a different
phosphorylation signal on the protein made in the dendrite versus
in the cell body.
“These studies highlight the importance of the dendritic environment
in modifying proteins after they have been made,” concludes
Eberwine. “There is a clear link between the nucleus and mitochondria
via Elk-1, and it’s rapid. We don’t know exactly what
that is, but it’s a very interesting signal in terms of neurodegeneration.
These data provide intriguing new avenues for research, including
determining the role of localized protein synthesis and protein
modifications in dendrite-related pathologies, including Fragile
X disease, schizophrenia, and autism. It is likely that not only
are particular proteins going to be important in these diseases,
which has been proven by genetics, but also the environment in which
they are synthesized.”
Study co-authors on the PNAS and Nature Methods paper are Hajime
Takano from Penn and Elisabeth J. Van Bockstaele from Thomas Jefferson
University, Philadelphia. This research was funded by the National
Institutes on Aging and the National Institutes of Mental Health.
###
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S.News &
World Report's most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students, the
School of Medicine is recognized worldwide for its superior education
and training of the next generation of physician-scientists and
leaders of academic medicine.
The University of Pennsylvania Health System includes three
hospitals [Hospital of the University of Pennsylvania, which is
consistently ranked one of the nation's few "Honor Roll"
hospitals by U.S.News & World Report; Pennsylvania Hospital,
the nation's first hospital; and Penn Presbyterian Medical Center];
a faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.